Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 13/20 | 0.43 |
| ▸ | JAK2 | O60674 | 12/20 | 0.43 |
| ▸ | JAK1 | P23458 | 12/20 | 0.43 |
| ▸ | SYK | P43405 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL650436 | 0.84 | JAK3 (0.44) | JAK3JAK2JAK1SYK | |
| SCHEMBL16948993 | 0.74 | MAPK1 (0.49) | JAK3JAK2JAK1SYK | |
| SCHEMBL16948771 | 0.70 | SYK (0.47) | JAK3JAK2JAK1SYK | |
| SCHEMBL16948770 | 0.69 | JAK3 (0.48) | JAK3JAK2JAK1SYK | |
| SCHEMBL651640 | 0.69 | SYK (0.44) | JAK3JAK2JAK1SYK | |
| SCHEMBL12673162 | 0.69 | PBRM1 (0.42) | SYK | |
| SCHEMBL12402514 | 0.65 | CDK8 (0.43) | JAK3JAK2JAK1SYK | |
| SCHEMBL12672910 | 0.65 | KDM4E (0.38) | JAK3JAK2JAK1SYK | |
| SCHEMBL16949171 | 0.65 | JAK3 (0.41) | JAK3JAK2JAK1SYK | |
| SCHEMBL4087542 | 0.64 | SMN1; SMN2 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119636-B2 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090215785-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215785-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, JAK2 | JAK3 7/4885JAK2 3/4885JAK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.